Rua takes $8.3m goodwill write-off as cash falls to $0.97m

What changed

Revenue rose to NZ$141.0k from NZ$62.8k in HY23 (+124.5%), but remains a sub-scale figure for a listed entity. Reported NPAT swung to a loss of NZ$10.9m from a profit of NZ$0.7m, with the entirety of the swing explained by a NZ$8.3m one-off goodwill impairment on a prior acquisition disclosed by management as "not delivered the expected financial returns." Tax was nil in both periods, so PBT and NPAT move identically and the cleaner operating read is the underlying loss after stripping the impairment, roughly NZ$2.6m versus NZ$0.7m profit prior (which itself benefited from fair-value gains).

Operating cash outflow narrowed to NZ$2.1m from NZ$3.7m, and capex was effectively zero (NZ$1.2k versus NZ$46.9k). Cash and equivalents fell to NZ$0.97m from NZ$1.71m a year ago. Total equity contracted to NZ$9.5m from NZ$26.7m, reflecting the impairment plus the carry of accumulated losses. No dividend was declared.

What matters

• The goodwill write-down is an admission, not a clean-up. Management explicitly states the acquisition has not delivered expected returns. While the NZ$8.3m hit is non-cash, it removes a third of prior equity and reframes the prior strategic rationale rather than reflecting a routine accounting refresh.
• Cash runway is now the dominant variable. At NZ$0.97m of cash against a six-month operating outflow of NZ$2.1m, the implied runway on the current burn rate is well under a year absent capital raising, asset sale, or a step-change in revenue. The improvement in operating cash outflow is real, but it is from a still-negative base.
• Revenue scale remains immaterial. The 124.5% YoY growth headline disguises that HY24 revenue is NZ$141k and is sequentially below the implied H2 FY23 run-rate of roughly NZ$294.9k. For a medicinal cannabis business pursuing export-led scale, this is not yet evidence that operating leverage is emerging.

Expectations

No quantified targets, forward-work disclosure, or formal guidance was provided in the supplied extracts. The shape context is therefore limited to the FY23 anchor: full-year FY23 revenue of NZ$357.7k implied an H2 FY23 run-rate near NZ$294.9k, against which HY24 at NZ$141.0k is a clear sequential step-down. The release notes distribution and channel initiatives (Australian sales appointment, Target Health distribution agreement) but does not attach revenue numbers to them. The result therefore supports a narrative of channel-building but does not yet support one of revenue acceleration.

Quality of result

Most of the reported deterioration is non-cash and one-off: the NZ$8.3m goodwill impairment is the singular driver of the loss expansion. Stripped of that, the underlying operating loss has widened modestly versus the prior comparable period once HY23 fair-value gains (which lifted that period's reported profit) are also normalised. Inventories rose 80.2% to NZ$248.6k, which is consistent with stock build for a launch phase but is also a use of working capital that is not visible in a margin metric because gross margin was not disclosed. The improvement in operating cash outflow looks genuine rather than working-capital flattered, since inventory built rather than released. The result is therefore loss-making but cash-controlled, with durability of any revenue gain unproven given the small base.

Unresolved

• What is the post-impairment carrying value of the acquired business, and is further impairment risk live if HY25 revenue does not inflect?
• What is the funding plan given NZ$0.97m cash against a NZ$2.1m half-year burn, and on what terms would equity be raised at the current equity base of NZ$9.5m?
• What is the gross margin on the NZ$141k of revenue, and how does export channel mix (Germany, Poland, Australia) split that figure?
• Are the new distribution agreements (Target Health, Australian sales head) accompanied by minimum volume commitments, and over what timeframe?

This briefing cannot assess the share-price reaction, market expectations going into the result, or the standalone economics of the impaired acquisition prior to write-down.

Key metrics

Analytical metrics

This analysis was generated using Annolyse, an AI-powered tool that analyses NZX company announcements. The analysis is based on available company filings and standard Annolyse calculations. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.